LGND

AcronymDefinition
LGNDLuminance Ground
LGNDDorsal Lateral Geniculate Nucleus (biology)
LGNDLateral Geniculate Nucleus Dorsalis
References in periodicals archive ?
Lemelson Capital Management (LCM), a private investment management firm, has announced that it had increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND), the company said.
Reducing fixture ground impedance, Lgnd, is effective and desirable.
Biopharma company Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) disclosed on Wednesday the launch of a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ.
Tickers featured: ALTH, AMGN, AVE, BIIB, BMY, CELG, DNA, GENZ, GILD, GNTA, GSK, ICOS, ILXD, IMCL, LGND, MICU, MLMN, ONYX, OSIP, PFE, PGNX, RHHVF, TLRK, TRMS, VRTX.
* Ligand Pharmaceuticals (NASDAQ: LGND) shares set a new yearly low of $90.97 this morning.
Release date- 30072019 - SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates.
(NASDAQ: LGND) and Switzerland-based SQ Innovation AG have entered into long-term, exclusive commercial license and supply agreements for use of Ligand's Captisol technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure, the companies said.
Ligand Pharmaceuticals Incorporated (LGND) announced that it will receive a $3M milestone payment as a result of the U.S.
US-based drugmaker Ligand Pharmaceuticals Inc.'s (NASDAQ: LGND) partner, Seelos Therapeutics, Inc.
(SAM226) PAUL MAIER - LIGAND PHARMACEUTICALS INC (LGND).
United States-based Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced yesterday that the company has signed a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand's Vernalis Design Platform.
This morning, Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Promacta Q4 revenue of $330M, above H.C.